drugset / Trial / NCT05845723
Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
This project aims to evaluate the efficacy and safety of the combination of glucocorticoids with tocilizumab or tofacitinib, compared to the traditional combination of glucocorticoids with cyclophosphamide in the treatment of vascular Behçet's syndrome.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2026-06-01
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 0.5 g | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Tofacitinib | Small molecule | 5 mg | Oral |